The therapeutic potential of probucol and probucol analogues in neurodegenerative diseases

被引：7

作者：

Sharif, Arazu ^{[1
,5
]}

Mamo, John ^{[1
,2
]}

Lam, Virginie ^{[1
,3
]}

Al-Salami, Hani ^{[1
,5
]}

Mooranian, Armin ^{[1
,5
]}

Watts, Gerald F. ^{[4
]}

Clarnette, Roger ^{[4
]}

Luna, Giuseppe ^{[5
]}

Takechi, Ryu ^{[1
,3
]}

机构：

[1] Curtin Univ, Fac Hlth Sci, Curtin Hlth Innovat Res Inst, Perth, WA, Australia

[2] Perron Inst Neurol & Translat Res, Perth, WA, Australia

[3] Curtin Univ, Fac Hlth Sci, Sch Publ Hlth, Perth, WA, Australia

[4] Univ Western Australia, Sch Med, Fac Hlth & Med Sci, Perth, WA, Australia

[5] Curtin Univ, Fac Hlth Sci, Curtin Med Sch, Perth, WA, Australia

来源：

TRANSLATIONAL NEURODEGENERATION | 2024年 / 13卷 / 01期

基金：

英国医学研究理事会;

关键词：

Neurodegenerative disease; Probucol; Probucol analogues; Inflammation; Blood-brain barrier; Oxidative stress; Amyloid-beta; BLOOD-BRAIN-BARRIER; AMYLOID-BETA PEPTIDE; CHOLESTEROL-LOWERING DRUG; OXIDATIVE STRESS; ALZHEIMERS-DISEASE; APOLIPOPROTEIN-E; SIGNALING PATHWAY; IN-VITRO; MITOCHONDRIAL DYSFUNCTION; ANTIOXIDANT BO-653;

D O I：

10.1186/s40035-024-00398-w

中图分类号：

Q189 [神经科学];

学科分类号：

071006 ;

摘要：

Neurodegenerative disorders present complex pathologies characterized by various interconnected factors, including the aggregation of misfolded proteins, oxidative stress, neuroinflammation and compromised blood-brain barrier (BBB) integrity. Addressing such multifaceted pathways necessitates the development of multi-target therapeutic strategies. Emerging research indicates that probucol, a historic lipid-lowering medication, offers substantial potential in the realm of neurodegenerative disease prevention and treatment. Preclinical investigations have unveiled multifaceted cellular effects of probucol, showcasing its remarkable antioxidative and anti-inflammatory properties, its ability to fortify the BBB and its direct influence on neural preservation and adaptability. These diverse effects collectively translate into enhancements in both motor and cognitive functions. This review provides a comprehensive overview of recent findings highlighting the efficacy of probucol and probucol-related compounds in the context of various neurodegenerative conditions, including Alzheimer's disease, Parkinson's disease, Huntington's disease, and cognitive impairment associated with diabetes.

引用

页数：12

共 126 条

[51] ApoE and Aβ in Alzheimer's Disease: Accidental Encounters or Partners? [J].

Kanekiyo, Takahisa ;

Xu, Huaxi ;

Bu, Guojun .

NEURON, 2014, 81 (04) :740-754

[52] QT-INTERVAL PROLONGATION PRODUCED BY PROBUCOL [J].

KLEIN, L .

ARCHIVES OF INTERNAL MEDICINE, 1981, 141 (08) :1102-1103

[53] AGIX-4207 [2-[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenoxy]acetic acid], a novel antioxidant and anti-inflammatory compound: Cellular and biochemical characterization of antioxidant activity and inhibition of redox-sensitive inflammatory gene expression [J].

Kunsch, C ;

Luchoomun, J ;

Chen, XL ;

Dodd, GL ;

Karu, KS ;

Meng, CQ ;

Marino, EM ;

Olliff, LK ;

Piper, JD ;

Qiu, FH ;

Sikorski, JA ;

Somers, PK ;

Suen, KL ;

Thomas, S ;

Whalen, AM ;

Wasserman, MA ;

Sundell, CL .

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2005, 313 (02) :492-501

[54] IL-1β promotes transendothelial migration of PBMCs by upregulation of the FN/α5β1 signalling pathway in immortalised human brain microvascular endothelial cells [J].

Labus, Josephine ;

Woeltje, Kerstin ;

Stolte, Kim Natalie ;

Haeckel, Sonja ;

Kim, Kwang Sik ;

Hildmann, Annette ;

Danker, Kerstin .

EXPERIMENTAL CELL RESEARCH, 2018, 373 (1-2) :99-111

[55] Interleukin-1β induces an inflammatory response and the breakdown of the endothelial cell layer in an improved human THBMEC-based in vitro blood-brain barrier model [J].

Labus, Josephine ;

Haeckel, Sonja ;

Lucka, Lother ;

Danker, Kerstin .

JOURNAL OF NEUROSCIENCE METHODS, 2014, 228 :35-45

[56] Efficacy of probucol on cognitive function in Alzheimer's disease: study protocol for a double-blind, placebo-controlled, randomised phase II trial (PIA study) [J].

Lam, Virginie ;

Clarnette, Roger ;

Francis, Roslyn ;

Bynevelt, Michael ;

Watts, Gerald ;

Flicker, Leon ;

Orr, Carolyn F. ;

Loh, Poh ;

Lautenschlager, Nicola ;

Reid, Christopher M. ;

Foster, Jonathan K. ;

Dhaliwal, Satvinder S. ;

Robinson, Suzanne ;

Corti, Emily ;

Vaccarezza, Mauro ;

Horgan, Ben ;

Takechi, Ryusuke ;

Mamo, John .

BMJ OPEN, 2022, 12 (02)

[57] How do immune cells overcome the blood-brain barrier in multiple sclerosis? [J].

Larochelle, Catherine ;

Alvarez, Jorge Ivan ;

Prat, Alexandre .

FEBS LETTERS, 2011, 585 (23) :3770-3780

[58] Reactive Astrocytes in Neurodegenerative Diseases [J].

Li, Kunyu ;

Li, Jiatong ;

Zheng, Jialin ;

Qin, Song .

AGING AND DISEASE, 2019, 10 (03) :664-675

[59]

Liu H-W., 2020, BioMed Research International, V2020

[60] Mitophagy in Parkinson's Disease: From Pathogenesis to Treatment [J].

Liu, Jia ;

Liu, Weijin ;

Li, Ruolin ;

Yang, Hui .

CELLS, 2019, 8 (07)

← 1 2 3 4 5 6 7 8 9 10 →